Company intelligence / Profile preview

Polyplus

Strasbourg/Illkirch, Grand Est, Francepolyplus.com ↗

Ownership: Private
Employees: ~270
Development stage: Commercial

Overview

Polyplus has established itself as a global leader in nucleic acid delivery solutions. Its transfection reagents and GMP-grade plasmids are critical components in the manufacture of viral vectors used in cell and gene therapies. The company’s products are widely used from research through commercial-scale biomanufacturing. No direct clinical results as it does not develop its own therapeutic pipeline but enables clinical programs industry-wide.

Modalities: Nucleic acid delivery technologies (including for DNA and RNA)Plasmid DNA manufacturingProtein manufacturingTransfection reagentsGene therapy vectors [viral and nonviral]mRNA-based drugsPlasmid DNA
Industry: Chemicals & Materials

Partnerships

Sartorius Group (parent)ARCHIMEDWarburg Pincus

Beyond the preview

Go deeper on Polyplus.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Polyplus.

Explore the full profile